Pleading to Invoke the "Bayh-Dole Act": August 4, 2020 Letter Signed by 48 Attorneys General, Based on Gilead's Price Gouging and Limiting the Remdesivir Supply

Followed by a new August 7, 2020 Gilead arrangement that will surprise you.

In a letter dated August 4. 2020, forty-eight Attorneys General “told” on Gilead’s deficiencies in cost and ability to supply remdesivir via a letter to HHS, the NIH, and the FDA.

We know that remdesivir was used in hospital “killing” protocols during the pandemic, skewing statistics that otherwise seemed to show increased deaths were from COVID. We also saw that Gilead’s more recent troubles involve a class action lawsuit filed by families who were adversely affected by the use of remdesivir in hospitals, alleging false advertising and lack of informed consent.

Three days after this August 4th letter, we found a surprising letter that provides more information on who else was manufacturing remdesivir.